ASX - Delayed Quote AUD

Immutep Limited (IMM.AX)

0.3020

+0.0020

+(0.67%)

As of 11:54:25 AM GMT+10. Market Open.

Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L NSCLC)Notably, ~92% of all evaluable patients have PD-L1 TPS <50%, including 43% with PD-L1 below 1 (TPS <1%), who represent an area of high unmet needData demonstrates significant improvement in response rates compared to historical controls, and safety continues to be favourableMulti-centre INSIGHT-003 is evaluating the same immunotherapy/chemotherapy combination used in t

GlobeNewswire 14 hours ago

IMMP

PRRUF
Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1

Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS <1Mature overall survival data builds on encouraging high response rates with multiple complete responsesPatients with CPS <1 represent a high unmet medical need and have no available treatment options without chemotherapyMeeting with FDA has now been requested to discuss next steps including potential paths to approval SYDNEY, AUSTRALIA, May 05,

GlobeNewswire 10 days ago

IMMP

PRRUF
Immutep Quarterly Activities Report Q3 FY25

Media Release First patient safely dosed in TACTI-004 Phase III lung cancer trial, marking a significant milestonePivotal TACTI-004 trial design presented at the European Lung Cancer Congress (ELCC) 2025Patient enrolment completed for the EFTISARC-NEO Phase II trial evaluating efti with radiotherapy and KEYTRUDA® in resectable soft tissue sarcomaPatient enrolment completed for the INSIGHT-003 Phase I trial evaluating efti with KEYTRUDA® and chemotherapy as first-line treatment of advanced or met

GlobeNewswire 16 days ago

IMMP

PRRUF
Immutep to Participate in Upcoming Investor Conferences

SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences: Jones Healthcare and Technology Innovation Conference Location:Las Vegas, NV Date: Wednesday, 9 April 2025 Time:4:30 pm ET The Citizens Life Sciences ConferenceLocation:New Yo

GlobeNewswire last month

IMMP

PRRUF
First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with efti will enrol approximately 756 patients at more than 150 clinical sitesTrial results will inform potential marketing approval application in non-small cell lung cancer, one of the largest indications in oncology SYDNEY, AUSTRALIA, March 25, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immun

GlobeNewswire last month

IMMP

PRRUF
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025

SYDNEY, AUSTRALIA, March 20, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for the pivotal TACTI-004 Phase III trial. The poster will be presented at the European Lung Cancer Congress (ELCC) 2025, taking place in Paris, France, from 26-29 March 2025. The Trial in Progress poster includes an overview and study design of the

GlobeNewswire last month

IMMP

PRRUF
Immutep Limited (IMMP): Among the Best Australian Stocks to Buy According to Billionaires

We recently published a list of 10 Best Australian Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Immutep Limited (NASDAQ:IMMP) stands against other best Australian stocks to buy according to billionaires. Australian Market Outlook 2025 In December 2024, Ausbil Investment Management Limited released its equity […]

Insider Monkey 2 months ago

IMM.AX
+0.67%
Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now?

We recently compiled a list of the 10 Best Long Term ASX Stocks to Buy Now. In this article, we are going to take a look at where Immutep Limited (NASDAQ:IMMP) stands against the other long term ASX stocks. Vanguard believes that Australia’s economy remains well-placed to recover gradually in 2025 after the broader economy witnessed […]

Insider Monkey 3 months ago

IMM.AX
+0.67%
Immutep Quarterly Activities Report Q2 FY25

Media Release Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approvalMature data from INSIGHT-003 in 1L NSCLC demonstrates an excellent 32.9-month median overall survival (OS) and 81.0% 24-month OS rate, significantly outperforming historical controlsPromising new results in first line head & neck cancer with PD-L1 CPS <1 reported at ESMO IO 2024, with median OS not reached a

GlobeNewswire 3 months ago

IMMP

PRRUF
Is Immutep Limited (IMMP) One of the Best ASX Stocks to Buy According to Hedge Funds?

We recently compiled a list of the 10 Best ASX Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Immutep Limited (NASDAQ:IMMP) stands against other best ASX stocks to buy according to hedge funds. According to a report by the Australian Bureau of Statistics (ABS) published […]

Insider Monkey 3 months ago

IMM.AX
+0.67%
Why Immutep (IMMP) Is Among the Best Australian Stocks to Buy Now?

We recently compiled a list of the 10 Best Australian Stocks to Buy Now. In this article, we are going to take a look at where Immutep Limited (NASDAQ:IMMP) stands against other best Australian stocks to buy now. According to a report by Vanguard published on January 24, Australia’s economy is expected to experience a gradual […]

Insider Monkey 3 months ago

IMM.AX
+0.67%
Patient Enrolment Completed for EFTISARC-NEO Phase II Trial

Phase II trial evaluating efti in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) in patients with soft tissue sarcoma reaches enrolment target of 40 patientsData updates from EFTISARC-NEO expected in 2025 SYDNEY, AUSTRALIA, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that patient enrolment has b

GlobeNewswire 3 months ago

IMMP

PRRUF
Immutep Limited (ASX:IMM) is largely controlled by institutional shareholders who own 51% of the company

Key Insights Institutions' substantial holdings in Immutep implies that they have significant influence over the...

Simply Wall St. 3 months ago

IMMP

PRRUF
Patient Enrolment Completed for INSIGHT-003

Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with non-small cell lung cancer reaches enrolment target of approximately 50 evaluable patientsData updates from INSIGHT-003 are expected in 2025 and beyond SYDNEY, AUSTRALIA, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today an

GlobeNewswire 4 months ago

IMMP

PRRUF
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to dateAdditional safety data and assessment of PK/PD relationships to follow in first half of CY2025IMP761 is designed to enhance the “brake” function of LAG-3 on T cells to restore balance to the immune system and address the underlying cause of many autoimmune diseases SYDNEY, AUSTRALIA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Compan

GlobeNewswire 4 months ago

IMMP

PRRUF
Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for development of blocking LAG-3 therapeutics, including Immutep’s anti-LAG-3 small molecule programData also supports eftilagimod alfa’s (efti) preferential binding to a subset of MHC Class II molecules on antigen-presenting cells leading to their activation SYDNEY, AUSTRALIA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Compan

GlobeNewswire 4 months ago

IMMP

PRRUF
Immutep announces results from Cohort B of TACTI-003 trial

Immutep (IMMP) announces positive clinical results from Cohort B of the TACTI-003 Phase IIb trial. This study evaluates eftilagimod alpha in combination with MSD’s anti-PD-1 therapy KEYTRUDA in first line recurrent/metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expression. Data as of the 31 October 2024 cut-off date in evaluable 1L HNSCC patients whose tumours express PD-L1 below 1 and who typically do not respond well to anti-PD-1 therapy alone shows: Positively,

TipRanks 4 months ago

IMMP

PRRUF
Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in difficult-to-treat head and neck cancer patients with PD-L1 CPS <1Positively, median overall survival (OS) has not yet been reached and the 12-month OS rate is 67%, both well above historical controlsComplete response rate increases to 12.9% and 16.1%, according to RECIST 1.1 and iRECIST, respectivelyTreatment continues to be well tolerated SYDNEY, AUS

GlobeNewswire 4 months ago

IMMP

PRRUF
Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Media Release SYDNEY, AUSTRALIA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the initiation of the pivotal TACTI-004 Phase III clinical trial for the treatment of first-line metastatic non-small cell lung cancer (1L NSCLC). “The receipt of regulatory approval from the Australian Therapeutic Goods Administrati

GlobeNewswire 5 months ago

IMMP

PRRUF
Exclusive: Prima, Mexico-based manufacturing and supply chain integrator, reveals it has raised $42.5 million

Prima raised $23 million in new Series A backing earlier this year, a few months before Donald Trump’s election victory.

Fortune 5 months ago

IMM.AX
+0.67%

Performance Overview

Return	IMM.AX	S&P/ASX 200 [XJO] (^AXJO)
YTD	-17.26%	+2.39%
1-Year	-30.57%	+6.00%
3-Year	-15.96%	+17.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Immutep Limited (IMM.AX)

Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1

Immutep Quarterly Activities Report Q3 FY25

Immutep to Participate in Upcoming Investor Conferences

First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025

Immutep Limited (IMMP): Among the Best Australian Stocks to Buy According to Billionaires

Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now?

Immutep Quarterly Activities Report Q2 FY25

Is Immutep Limited (IMMP) One of the Best ASX Stocks to Buy According to Hedge Funds?

Why Immutep (IMMP) Is Among the Best Australian Stocks to Buy Now?

Patient Enrolment Completed for EFTISARC-NEO Phase II Trial

Immutep Limited (ASX:IMM) is largely controlled by institutional shareholders who own 51% of the company

Patient Enrolment Completed for INSIGHT-003

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

Immutep announces results from Cohort B of TACTI-003 trial

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Exclusive: Prima, Mexico-based manufacturing and supply chain integrator, reveals it has raised $42.5 million

Performance Overview